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Angiogenesis is new blood vessel formation, a process that can lead to tumor development. Microvessel count has been
correlated to metastasis in some neoplasias.
PURPOSE: To determine if measurement of microvessel density is useful in predicting metastasis to the cervical lymph
node and prognosis in patients with papillary thyroid carcinoma.
METHODS: A retrospective analysis was performed in 30 patients that had undergone total thyroidectomy. They were
divided in 2 groups of 15 patients — with and without metastatic disease. Immunohistochemistry was used to detect
expression of CD34 in archival paraffin-embedded papillary thyroid tumors, and microvessel density was calculated based
on it. Association between microvessel density and the presence of metastasis, according to histological subtype, disease
recurrence, and AMES prognostic index groups was determined through statistical analysis.
RESULTS: The median microvessel density for the patient group without metastasis (200.0 microvessels/mm2) was apparently,
but not significantly, less than that observed among metastatic disease patients (254.4 microvessels/mm2) (P = .20). When
papillary carcinoma subtypes were analyzed, this difference became significant (P =.02). The follicular variant exhibited a
greater microvessel density than the other subtypes, independent of metastasis presence. There was an apparent, but not
significant, tendency for a larger median microvessel density in the group of patients that presented recurrence (294.4
microvessels/mm2 vs 249.6 microvessels/mm2, P = .11). There was no relationship between risk level and microvessel
density: in the low- and high-risk groups, the median MVD was 304.0 microvessels/mm2 and 229.6 microvessels/mm2,
respectively (P = .27).
CONCLUSIONS: The results suggest that angiogenesis is more intense among metastatic tumors in the classic and the tall
cell variants, indicating that microvessel count can be an indicator of the potential for metastasis in these subtypes of
papillary thyroid carcinoma. Patients that developed recurrent disease had a tendency to exhibit higher angiogenesis;
however, there was no association between microvessel density and the AMES prognostic index.
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Papillary thyroid carcinoma is classified as a well-dif-
ferentiated carcinoma, and it is the most common malig-
nant neoplasia of endocrine origin. Although it usually has
a good prognosis and is curable in most well-treated cases,
recurrent disease can reach 20%, in the presence of local
invasion and metastasis, while management in these cases
is still a challenge. Thus, a considerable number of research
projects has been carried out to identify prognostic factors
that would make it possible to classify these patients into
risk groups according to a prognostic scoring system.1-6
Cervical lymph node involvement in papillary thyroid
carcinoma has not been considered a bad prognostic fac-
tor. In spite of this, there are reports of higher mortality and
local recurrence when cervical lymph node involvement
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occurs in older patients.1,4,5 Moreover, neck dissection is
necessary in such cases, which, requires in the least more
surgical procedure. These facts, along with the findings that
even low-risk tumors can develop into aggressive disease,
demonstrate that there is a need to develop methods to bet-
ter characterize the well-differentiated carcinoma, which
would help achieve an adequate therapeutic approach.6 Bio-
logical markers capable of identifying increased risk of me-
tastasis development can contribute to an objective recog-
nition of high-risk tumors.
Angiogenesis, the generation of new blood vessels, is
crucial for tumor growth and metastasis development. In
neoplastic diseases, it is stimulated by factors produced by
tumor cells. Biological markers related to this process could
be useful for diagnosis and identification of the prognosis
in malignant diseases. Evidence that antiangiogenic
therapy inhibits growth of some tumors attests to the im-
portance of studying such markers.7,8
Some angiogenic factors—fibroblast growth factors
(FGF) and vascular endothelial growth factors(VEGF) —
have been identified that undergo increased expression by
several kinds of solid tumors.9-12 It is also known that the
number of new blood vessels is greater in neoplastic tissue
than in normal tissue.6,13,14 Metastatic thyroid tumors have
a greater immunohistochemical expression of VEGF,15 and
an altered expression of genes associated with angiogen-
esis was found in metastatic follicular thyroid carcinoma.16
The first reports of a relationship between metastasis and
the number of tumor blood vessels were by Srivastava17 in
1988, in melanoma studies, and Weidner18 in 1992, who
compared microvessel density (MVD) with breast carcinoma
prognosis. Since then, studies have indicated the possibil-
ity of a correlation between microvessel count, which is a
measure of tumor angiogenesis, and formation of regional
metastasis in different malignant neoplasms.19,20 However,
in thyroid carcinoma, the value of MVD as a prognostic
indicator and its role in metastasis development has re-
mained controversial.
The number of microvessels in undifferentiated thyroid
tumors was found to be very low, and only in medullary
carcinoma was the highest MVD a significant prognostic
factor.21 Microvessel density was higher in well-differenti-
ated thyroid carcinoma when compared to adjacent normal
thyroid tissue, but was not correlated to poor outcome.6
Similar results were found in follicular neoplasms.22 On the
other hand, other investigators found that MVD can be a
significant prognostic indicator in papillary thyroid carci-
noma.23,24
Our purpose was to compare MVD between 2 homoge-
neous groups of patients with papillary thyroid carcinoma—
with or without cervical node metastatic disease — to de-
termine if angiogenesis measurement can indicate the meta-
static potential and prognosis for papillary thyroid carci-
noma.
METHODS
Following the approval of the Institutional Committee
on Ethics and Research we studied 30 patients treated for
papillary thyroid carcinoma who had undergone thyroid-
ectomy during the period of January 1997 to February 1998.
They were distributed into 2 groups:
- Group 1: 15 patients without metastasis at diagnosis;
- Group 2: 15 patients with metastasis at diagnosis.
The following background data were collected: physi-
cal examination of the cervical area; preoperative exams;
treatment carried out (extent of the operation, complemen-
tary radio iodine therapy); pathological features; postop-
erative exams; and clinical evolution.
Morphological evaluation and immunohistochemistry
assay
After a histological review, the papillary carcinomas and
their histological subtypes were classified according to the
AFIP25 criteria. A representative tumor area was considered
for immunohistochemical analysis.
Immunohistochemistry was performed on thin sections
(3 µm) of previously formalin-fixed and paraffin-embedded
tissues, following the standard avidin-biotin-peroxidase
complex method. Tumor sections were stained with anti-
endothelial cell antibody, the mouse monoclonal antibody
CD34 (Lyophilized Monoclonal - NCL-END, Novocastra®,
1:600 dilution). Immunoreaction was visualized using
diaminobenzidine (DAB) as the chromogen.
Areas of greater concentration of stained vessels (hot
spots) were identified at low magnification. Ten fields at
400x magnification were then studied within these areas,
and the immunohistochemistry index was determined by
the point counting26 technique, making it possible to ob-
tain the number of microvessels stained positively in the
studied tumor area.
Prognostic evaluation
Since there is no mortality related to papillary carci-
noma, only a Kaplan-Meyer disease-free survival study was
performed. We also classified all patients into risk groups
according to the AMES4 prognostic index, where “A” rep-
resents age, “M” distant metastasis, “E” extrathyroidal ex-
tension, and “S” the largest diameter of the tumor. Age is
the prognostic factor related to the patient, while all others
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constitute factors related to the tumor which can be classi-
fied as:
– Low-risk: absence of distant metastasis and of extra-
thyroidal extension; largest tumor diameter ≤40 mm;
– High-risk: presence of distant metastasis, or extra-
thyroidal extension, or largest tumor diameter >40 mm.
Patients were finally distributed into 3 risk groups as
shown in Table 1.
Results evaluation
For statistical analysis, the software package SPSS® 11.0
for Windows® 2000 was used, and a 5% (P <.05) signifi-
cance level was adopted. Comparison between classified
variables was assessed by the Fisher exact test. Since the
test of normality revealed that this study group was not para-
metric (P = .078), comparison between the medians of the
continuous variables was performed through Mann-Whitney
and Kruskal-Wallis tests. For correlation studies, the
Spearman rank correlation test was applied.
RESULTS
Patients
The average age was 46.7 ± 18.9 years (mean ± SD;
range, 14-75 years). There was no difference in age between
groups: In group 1, the average age was 47.9 ± 20 years,
and in group 2, it was 45.5 ± 18.3 years (P = .73). Only 1
man was included in the study, belonging to group 2.
No difference was detected between groups regarding
physical examination, nor regarding the presence of antithy-
roid antibodies.
Total thyroidectomy was performed in all cases, com-
plemented by neck dissection if lymph node metastasis was
present. Whole body scintigraphy with iodine was carried
out in all but 1 of the cases. No patient presented distant
metastasis at diagnosis.
The median follow-up time was 59.4 ± 14 months (range
12-72 months). The postoperative marker of recurrence was
the curve of the thyroglobulin serum level. Recurrence oc-
curred in 6 (20%) patients in an average time of 26.7
months. Recurrences occurred mainly in group 2 (P = .04).
The Kaplan-Meyer disease-free survival was 71% in 5
years.
Morphologic evaluation
The papillary thyroid carcinoma histological subtypes
found were: classic papillary carcinoma in 19 cases
(63.3%); tall cell in 5 cases (16.7%); and follicular in 6
cases (20%).
The average tumor size was 23.83 ± 2.5 mm.
Microcarcinomas (<10.0 mm) represented 17% of the
tumors, while 73% exhibited sizes between 11 and 40 mm
at the largest diameter; 10% of the tumors were greater than
40 mm in diameter. There was no difference in size between
groups 1 and 2 (P =.79).
When we analyzed characteristics of local invasion, we
found that 13 (43.3%) of tumors exhibited extrathyroidal
extension, 10 (33.3%) vascular invasion, 7 (23.3%)
perineural invasion, 12 (40%) lymphatic invasion, and 19
(63.3%) were multicentric tumors.
Microvessel density analysis (MVD)
The pattern of CD34 antibody expression in papillary
thyroid carcinoma can be seen in Figure 1. There is posi-
Table 1 – Risk groups according to AMES4 prognostic index.
Group Low Risk Intermediate Risk High Risk
Patient < 45 years old < 45 years old ≥ 45 years old ≥ 45 years old
Tumor Low Risk High Risk Low Risk High Risk
Figure 1 – CD34 staining aspect in papillary thyroid carcinoma. 40x (A), 100x (B) and 400x (C) magnification. The brown-dark represents
endothelial cells stained by CD34 antibody in blood vessels of the papillary fibrovascular axis.
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tive staining in the cytoplasm of endothelial cells, mainly
inside the fibrovascular axis of the formed papillae.
The median MVD for all patients was 249.6
microvessels/mm2 (range, 72.0-622.4 microvessels/mm2). In
group 1, the median MVD was 200.0 microvessels/mm2
(range, 72.0-622.4 microvessels/mm2), and in group 2, it was
254.4 microvessels/mm2 (range, 179.2-544.0 microvessels/
mm2) (P = .20).
A high MVD was found in the follicular subtype (me-
dian of 354.4 microvessels/mm2) when compared to other
histological subtypes (tall cell, median MVD of 179.2
microvessels/mm2; classic subtype, median MVD of 236.8
microvessels/mm2), independent of the presence of metas-
tasis (Figure 2). In addition, the number of follicular
subtypes was larger in the patient group without lymph
node metastasis (Table 2). Therefore, when we analyzed only
classic and tall cell variants in both groups, the median
MVD was smaller in group 1 (179.0 microvessels/mm2;
range, 72.0-436.8 microvessels/mm2) than in group 2 (272.0
microvessels/mm2; range, 179.2-544.0 microvessels/mm2)
(P = .02), as shown in Figure 3.
Regarding patient age, the median MVD was 252.0
microvessels/mm2 in the group with ages less than 45 years
and 229.6 microvessels/mm2 in the group with ages greater
than 45 years (P = .26). There was no correlation between
age and MVD (Spearman correlation coefficient = –0.28, P
= .14).
The distribution of patients according to the AMES in-
dex, and the median MVD of each risk group, are presented
in Table 3.
The median MVD in the patient group that developed
recurrence was 294.4 microvessels/mm2 and for those who
did not experience recurrence was 249.6 microvessels/mm2
(P = .11).
Table 2 – The MDV (microvessels/mm2) median of risk
groups according to AMES4 prognostic index.
Risk Groups Number of Cases MDV Median*
Low Risk 8(27%)** 304,0
Intermediate Risk 14(46%)** 224,8
High Risk 8(27%)** 229,6
* microvessels/mm2, p=0,27; Kruskal-Wallis test.
** percentage of patients total.
Figure 2 – The CD34 antibody expression in classic papillary carcinoma subtype, at 40X (A) and 400x (B) magnification; and in follicular one,
at 40x (C) and 400x (D) magnification showing the higher number of microvessels in follicular papillary carcinoma subtype.
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DISCUSSION
It is important to determine the prognosis case by case
in the process of choosing the appropriate treatment. Most
patients present extremely favorable evolution, which is
sometimes not related to the extent of surgical resection.
However, some cases have a poor outcome and previously
there have been no objective criteria to separate them.
The importance of angiogenesis has long been described
in tumor progression and metastasis formation.7 Methods
that enable quantification of angiogenesis have been de-
veloped to evaluate its role in the prognosis of different
tumors. Regarding thyroid carcinoma, quantification of an-
giogenesis has been reported in a few studies. In Brazil, the
expression of CD34 in follicular thyroid neoplasm was stud-
ied in a single study.22
This research analyzed MVD in thyroid papillary carci-
noma in a case-control (metastatic disease vs no metastatic
disease) study using CD34 immunostaining. Other markers
can be used, but CD34 has proved to be better than factor
VIII and CD31 in previously paraffin-embedded tissues.27,28
In this series, the findings regarding MVD were tested
statistically, increasing the reliability of the conclusions.
There was similarity among the groups, regarding pa-
tient age, tumor nodule size, and applied treatment. The fre-
quency of recurrent disease was higher in cases that devel-
oped metastases, similar to that found by other authors.2,3,5
We found a median MVD of 249.6 microvessels/mm2,
which is similar to that (202.1 microvessels/mm2) observed
by Livolsi and Asklen.13
When groups with and without metastasis were consid-
ered, we noticed that there was a tendency to higher angio-
genesis in the metastatic disease group (group 2), as has
been shown by other authors.6,13 Evaluation considering
only classic and tall cells subtypes had significantly greater
MVD in group 2. This means that quantitative angiogen-
esis analysis can be considered as a tool for identifying the
higher potential of metastasis development in those histo-
logical subtypes. To investigate this hypothesis in the
follicular variant, other studies are necessary involving larger
numbers of this tumor subtype. Several studies have shown
that follicular carcinoma has a higher MVD than papillary
carcinoma,6,21,29,30 a point which had already been docu-
mented in studies with VEGF.16 It is interesting to note that
the follicular variant of papillary carcinoma had
microvessel patterns that were similar to those described in
follicular carcinoma, and in spite of the high MVD, there
was no correlation with the occurrence of lymph node me-
tastasis. This finding is in agreement with the fact already
demonstrated1 that follicular carcinoma has a greater ten-
dency towards hematogenic metastasis. On the other hand,
the high MVD developed in the follicular variant suggests
Figure 3 – MVD (microvessels/mm2) comparison between groups without and with metastasis, considering all patients (A) and after follicular
subtype exclusion in both groups (B).
* Mann-Whytney test.
Table 3 - The MDV median of risk groups according to
AMES4 prognostic index.
Risk groups Number of cases MVD median*
Low risk 8 (27%) 304.0
Intermediate risk 14 (46%) 224.8
Higth risk 8 ( 8%) 229.6
Total 30 (100%) 249.6
* microvessels/mm2, p= 0,27; Kruskal-Wallis test
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that angiogenesis quantification can aid in differential di-
agnosis of follicular neoplasms, a point which also needs
to be studied in future investigations.
Microvessel density has been shown to keep an inverse
relationship to patient age at diagnosis, diameter, and ex-
tent of the primary tumor.13 This unexpected finding was
thought to be explained by the previous findings that
poorly-differentiated carcinomas exhibit smaller
microvessel numbers.21,22,30 Accordingly, the present study
revealed a tendency for the lowest MVD to exist in locally
invasive tumors and in patients older than 45 years.
The Kaplan-Meier disease-free survival test was not ap-
propriate because there was an insufficient number of pa-
tients in each group studied. Therefore, the AMES4 prog-
nostic index was used, and we found that the MVD was not
greater in the high-risk patient group. Livolsi and Asklen13
also found that decreased survival was not predicted by high
microvessel counts. Perhaps this occurred because poorly
differentiated carcinomas have low angiogenesis and are
related to worse prognosis.
In our study, tumors in patients with recurrent disease
tended to develop more angiogenesis. Fontanini et al.21 did
not observe a significant relationship between prognosis
and MVD. However, it should be noted that patients who
died had a greater median MVD than surviviors. Using the
European Organization Research on Treatment of Cancer
(EORTC) prognostic index, Wong29 found an association
between angiogenesis and prognosis in follicular carcinoma,
but not in papillary carcinoma.
CONCLUSION
Our results suggest that angiogenesis is more intense
among the classic and tall cell variants of metastatic tumors,
showing that microvessel count can be an indicator of meta-
static potential in these histological subtypes of papillary
thyroid carcinoma.
Patients that developed recurrent disease had a tendency
to exhibit higher angiogenesis; however, there was no as-
sociation between MVD and prognostic index groups.
Finally, our data demonstrated the importance of the
study of angiogenesis in papillary thyroid carcinoma.
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RESUMO
Stabenow E, Tavares MR, AM Ab´Saber, ER Parra-Cuentas,
LL de Matos, Eher EM et al. Angiogênese como indicador
do potencial de metástase no carcinoma papilífero
tireóideo. Clinics. 2005;60(3):233-40.
O desenvolvimento dos tumores depende da formação de
neovasos, a angiogênese. Em algumas neoplasias, a alta
densidade de microvasos tumorais correlaciona-se com a
presença de metástase.
OBJETIVO: Determinar se a medida da angiogênese pode
indicar o potencial de metástase e o prognóstico do carci-
noma papilífero tireóideo.
MÉTODO: Foi feita análise retrospectiva de 30
tireoidectomizados, divididos em dois grupos de 15
indivíduos cada, respectivamente com e sem metástase. A
partir dos blocos de parafina, foi calculada a densidade de
microvasos no tecido tumoral por meio da quantificação
da expressão do anticorpo CD34 pela imunohistoquímica.
A associação da densidade de microvasos com a presença
de metástase, ocorrência de recidiva e os grupos de risco
do índice prognóstico AMES foi determinada por análise
estatística.
RESULTADOS: A mediana da densidade de microvasos no
grupo de doentes sem metástase (200,0 microvasos/mm2)
foi inferior àquela dos portadores de metástase (254,4
microvasos/mm2) (p = .2), sem atingir significância
estatística. Ao considerar apenas os subtipos histológicos
clássico e de células altas, essa diferença tornou-se
significante (p = .02), uma vez que a variante folicular
exibiu maior DMV que os demais subtipos, independente
da presença de metástase. Houve tendência não significativa
à maior densidade de microvasos entre aqueles que
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